Sionna Therapeutics, Inc.

Contributing Author

Recent Articles by Sionna Therapeutics, Inc.

Sep-14	Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial SION +5.22% SION -16.71% GlobeNewswire
Aug-10	Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update SION -91.18% GlobeNewswire
Aug-06	Sionna Therapeutics Reports Second Quarter 2026 Financial Results SION GlobeNewswire
May-27	Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences SION GlobeNewswire
May-13	Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference SION +5.32% GlobeNewswire
May-12	Sionna Therapeutics Reports First Quarter 2026 Financial Results SION -10.90% GlobeNewswire
Apr-27	Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis SION GlobeNewswire
Apr-07	Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium SION GlobeNewswire
Mar-02	Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results SION -7.17% GlobeNewswire
Feb-23	Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences SION GlobeNewswire
Feb-04	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 SION -7.12% GlobeNewswire
Jan-05	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference SION GlobeNewswire
Nov-24	Sionna Therapeutics to Participate in Upcoming December Investor Conferences SION GlobeNewswire
Nov-05	Sionna Therapeutics Reports Third Quarter 2025 Financial Results SION GlobeNewswire
Nov-04	Sionna Therapeutics to Participate in Upcoming November Investor Conferences SION GlobeNewswire
Oct-24	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Oct-21	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis SION +31.99% GlobeNewswire
Oct-01	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference SION GlobeNewswire
Sep-08	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer SION -9.92% GlobeNewswire
Aug-27	Sionna Therapeutics to Participate in Upcoming September Investor Conferences SION GlobeNewswire
Aug-25	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis SION GlobeNewswire
Aug-11	Sionna Therapeutics Reports Second Quarter 2025 Financial Results SION +13.36% GlobeNewswire
Jun-06	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model SION +7.42% GlobeNewswire
Jun-04	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis SION +9.12% GlobeNewswire
Jun-03	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference SION GlobeNewswire
May-22	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference SION GlobeNewswire
May-12	Sionna Therapeutics Reports First Quarter 2025 Financial Results SION GlobeNewswire

Sionna Therapeutics, Inc.

Recent Articles by Sionna Therapeutics, Inc.

Upgrade your Finviz experience